Long-Term Effect of Maintenance Electroconvulsive Therapy in Patients With Depression-Data From a Small Randomized Controlled Trial.
Journal
The journal of ECT
ISSN: 1533-4112
Titre abrégé: J ECT
Pays: United States
ID NLM: 9808943
Informations de publication
Date de publication:
18 Jan 2024
18 Jan 2024
Historique:
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
17
1
2024
Statut:
aheadofprint
Résumé
This study aimed to compare the long-term effects of maintenance electroconvulsive therapy (M-ECT) with medication and medication only in patients with depression. A randomized controlled trial of 1 year of M-ECT with medication or medication only investigated relapse/recurrence among 56 patients in remission after electroconvulsive therapy (ECT) for depression was conducted. The results of the first year are published already and showed a significant advantage of M-ECT with medication.The current study was a long-term follow-up. When the randomized treatment allocation ended, medication was continued in both groups but M-ECT was terminated. Patients were followed for up to 10 years via Swedish national registers until the study endpoint of a new psychiatric diagnosis as an inpatient, suicide, suspected suicide, or death of another cause. Time to relapse was compared between the M-ECT with medication group and the medication-only group using Kaplan-Meier estimates. The median follow-up time was 6.5 years for the M-ECT and medication group and 3.1 years for the medication-only group. One year after randomization 22 patients remained in the M-ECT and medication group, and 14 patients remained in the medication-only group. Relapse patterns between the treatment groups after the completion of M-ECT seemed to be similar according to visual inspection. This long-term follow-up study suggests that most of the benefit achieved during the treatment period with M-ECT is maintained over several years, but the small sample size, with accompanying large statistical imprecision, makes the results uncertain. More long-term studies of M-ECT are required.Trial registration: ClinicalTrials.gov identifier: NCT00627887.
Identifiants
pubmed: 38232249
doi: 10.1097/YCT.0000000000000983
pii: 00124509-990000000-00129
doi:
Banques de données
ClinicalTrials.gov
['NCT00627887']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Uppsala-Örebro Regional Research Council and Research Committee of Örebro County Council, Örebro, Sweden, supported the research. A.N. has received lecturer honoraria from Lundbeck outside the submitted work. The other authors have no conflicts of interest or financial disclosures to report.
Références
Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299–1307.
Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63:1337–1344.
Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328:839–846.
Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57:425–434.
Youssef NA, McCall WV. Relapse prevention after index electroconvulsive therapy in treatment-resistant depression. Ann Clin Psychiatry. 2014;26:288–296.
Dar H, Vuthaluru K, Folajimi A, et al. Effectiveness of electroconvulsive therapy for preventing relapse and recurrence of depression in adults with major depressive disorder: an updated meta-analysis of randomized clinical trials. Cureus. 2023;15:e35683.
Navarro V, Gasto C, Torres X, et al. Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. Am J Geriatr Psychiatry. 2008;16:498–505.
Gagne GG Jr., Furman MJ, Carpenter LL, et al. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry. 2000;157:1960–1965.
Koh AHK, Tan XW, Tor PC, et al. The association between outpatient continuation/maintenance electroconvulsive therapy, readmission risk and total direct cost in patients with depressive, bipolar and psychotic disorders: a naturalistic retrospective cohort study. J Affect Disord. 2023;338:289–298.
Huuhka K, Viikki M, Tammentie T, et al. One-year follow-up after discontinuing maintenance electroconvulsive therapy. J ECT. 2012;28:225–228.
Lambrichts S, Vansteelandt K, Crauwels B, et al. Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic. Acta Psychiatr Scand. 2021;144:230–237.
Van de Velde N, Geerts PJ, Tandt H, et al. Discontinuation of continuation or maintenance electroconvulsive therapy caused by the COVID-19 pandemic: a naturalistic study investigating relapse in patients with major depressive disorder. J ECT. 2021;37:230–237.
Cabelguen C, Caillet P, Poulet E, et al. Recurrence after stopping maintenance electroconvulsive therapy: a retrospective case series. J ECT. 2020;36:265–271.
Nordenskjold A, von Knorring L, Ljung T, et al. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial. J ECT. 2013;29:86–92.
Elvin T, Nordenskjöld A. Årsrapport 2020. Region Örebro län. Örebro 2021. Available at: ect.registercentrum.se. Accessed November 29, 2023.
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
Socialstyrelsen. Internationell klassifikation av sjukdomar och relaterade hälsoproblem - Systematisk förteckning, svensk version 2011 (ICD-10-SE). Stockholm: Socialstyrelsen; 2010.
Brooke HL, Talback M, Hornblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765–773.
Socialstyrelsen. The Swedish Prescribed Drug Register. 2020. Available at: https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-swedish-prescribed-drug-register/. Accessed July 30, 2021.